Seven Fleet Capital Management LP Invests $510.24 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Seven Fleet Capital Management LP purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, Holdings Channel reports. The firm purchased 51,024 shares of the biotechnology company’s stock, valued at approximately $510,240,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Corient Private Wealth LP bought a new stake in BioCryst Pharmaceuticals during the second quarter worth about $1,430,000. Bank of America Corp DE bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $48,013,000. Man Group plc acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $7,329,000. Jupiter Topco LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $95,268,000. Finally, Elmind Capital LP bought a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $5,200,000,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on BCRX shares. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Needham & Company LLC reduced their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada decreased their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $9.83 on Thursday. The company’s 50 day moving average price is $9.68 and its two-hundred day moving average price is $9.02. The firm has a market capitalization of $2.51 billion, a P/E ratio of -6.55 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter last year, the business posted $0.15 EPS. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.